Sandoz enters agreement to develop non-opioid pain relief
Sandoz has entered into a development and commercialisation agreement with pharmaceutical company Durect to develop the drug Posimir (Saber-bupivacaine).
If you don't have a login or your access has expired, you will need to purchase a subscription to gain access to this article, including all our online content.
For more information on individual annual subscriptions for full paid access and corporate subscription options please contact us.
To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.
For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk
22 January 2018 Germany-based Sandoz has entered into a partnership with Biocon to develop, manufacture and commercialise biosimilars in immunology and oncology.
22 January 2018 Germany-based Sandoz has entered into a partnership with Biocon to develop, manufacture and commercialise biosimilars in immunology and oncology.
22 January 2018 Germany-based Sandoz has entered into a partnership with Biocon to develop, manufacture and commercialise biosimilars in immunology and oncology.